Helen Usansky
About Helen Usansky
Helen Usansky serves as the Sr. Director and Head of Clinical Pharmacology at Insmed Incorporated, bringing over 25 years of experience in pharmaceutical research and development. She holds a PhD in Pharmaceutical Sciences from Rutgers University and has worked in various leadership roles across notable companies in the industry.
Work at Insmed
Helen Usansky serves as the Sr. Director and Head of Clinical Pharmacology at Insmed Incorporated. She has held this position since 2020, contributing to the company's efforts in drug development and clinical research from their Bridgewater, New Jersey location. Her role involves overseeing clinical pharmacology initiatives and ensuring compliance with regulatory standards.
Education and Expertise
Helen Usansky has a robust educational background in the pharmaceutical sciences and medicine. She earned her PhD in Pharmaceutical Sciences from Rutgers University, where she studied from 2000 to 2004. Additionally, she holds an MD from China Medical University and an MSc in Pharmacology & Pharmacokinetics from Dalian Medical University. Her expertise spans multiple therapeutic areas, including immunology, oncology, cardiology, pulmonology, hematology, urology, dermatology, and ophthalmology.
Background
Helen Usansky has over 25 years of experience in pharmaceutical research and development. She has worked in various capacities at several pharmaceutical companies, including Bristol-Myers Squibb, where she was a Senior Research Investigator in Clinical Discovery, and Allergan, where she served as a Scientist in Pharmacokinetics and Drug Metabolism. Her career also includes leadership roles at Asana BioSciences and Ikaria, where she focused on clinical pharmacology and translational medicine.
Achievements
Throughout her career, Helen Usansky has demonstrated significant leadership and hands-on skills in clinical pharmacology, modeling and simulation, and drug metabolism and pharmacokinetics (DMPK). She has extensive experience in defending drug development programs to global health authorities and possesses a comprehensive understanding of translational and clinical drug development for various drug formats, including small molecules and biologics.